Browse Studies — Arctuva

A Prospective, US-Based Study Assessing Mogamulizumab-Associated Rash in Patients Diagnosed With Mycosis Fungoides or Sézary Syndrome and Treated With Standard of Care Mogamulizumab

This study is being done to assess mogamulizumab-associated rash in patients diagnosed with mycosis fungoides or sezary syndrome and treated with standard of c…

Recurrent Mycosis FungoidesRecurrent Sezary SyndromeRefractory Mycosis Fungoides+6 more

Estimated

~$10 – $750

City of Hope Medical CenterNCT07003100

Phase 1

A Phase 1/2 Trial of Durvalumab (MEDI4736) When Given as a Single Agent or in Combination With Lenalidomide in Patients With Relapsed/ Refractory Peripheral T-cell Lymphoma, Including Cutaneous T-cell Lymphoma

This randomized phase I/II trial studies the best dose and side effects of durvalumab and to see how well it works with or without lenalidomide in treating pat…

Folliculotropic Mycosis FungoidesRecurrent Cutaneous T-Cell Non-Hodgkin LymphomaRecurrent Mycosis Fungoides+5 more

Estimated

~$10 – $6,250

City of Hope Medical CenterNCT03011814

Phase 1

MC1684 Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, Lymphomas, or Histiocytic/Dendritic Cell Neoplasms

This phase I trial studies the best dose and side effects of the VSV-hIFNβ-NIS vaccine with or without cyclophosphamide and combinations of ipilimumab, nivolum…

B-Cell Non-Hodgkin LymphomaHistiocytic and Dendritic Cell NeoplasmMyelodysplastic Syndrome+16 more

Estimated

Prospective Observational Trial of Low-Dose Total Skin Electron Therapy in Mycosis Fungoides Using Rotisserie Technique

This clinical trial studies low- dose total skin electron therapy in treating patients with stage IB-IIIA mycosis fungoides that has not responded to previous …

Recurrent Mycosis FungoidesRefractory Mycosis FungoidesStage I Mycosis Fungoides+2 more

Estimated

~$10 – $750

Vanderbilt-Ingram Cancer CenterNCT02702310